Rallybio Corp
RLYBNasdaqCIK 1739410HealthcareFiscal year ends Dec 31
Latest reported revenue, Q3 FY2026$0Revenue, Q3 FY2026, three months to 2026-09-30$0. XBRL concept
us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figureThree months to Sep 30, 2026, from the 10-Q filed Oct 27, 2026.Latest quarter: Q3 FY2026
Three months to Sep 30, 2026, against the same quarter a year earlier.
- Revenue$0Revenue, Q3 FY2026, three months to 2026-09-30$0. XBRL concept
us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figureSign changed from a year earlier - Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
- Operating marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Net marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
- Diluted EPS−$0.48Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.48 per share. XBRL concept
us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figureSign changed from a year earlier - Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare
Last eight quarters
Full statements| Line item | Unit | Q4 FY20242024-12-31 | Q1 FY20252025-03-31 | Q2 FY20252025-06-30 | Q3 FY20252025-09-30 | Q4 FY20252025-12-31 | Q1 FY20262026-03-31 | Q2 FY20262026-06-30 | Q3 FY20262026-09-30 | Shape over the periods |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $k | 38.0Revenue, Q4 FY2024, three months to 2024-12-31$38.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Report this figure | 212Revenue, Q1 FY2025, three months to 2025-03-31$212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | 212Revenue, Q2 FY2025, three months to 2025-06-30$212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-053880.Report this figure | 212Revenue, Q3 FY2025, three months to 2025-09-30$212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figure | 222Revenue, Q4 FY2025, three months to 2025-12-31$222.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Report this figure | 212Revenue, Q1 FY2026, three months to 2026-03-31$212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | 0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-053880.Report this figure | 0.0Revenue, Q3 FY2026, three months to 2026-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | (30547.4%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$11.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Revenue: $38.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Report this figure | (4561.3%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$9.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | (4743.9%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$10.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053880.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-053880.Report this figure | (3266.5%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$6.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figure | (2888.3%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Revenue: $222.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Report this figure | (4119.3%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$8.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Net margin | % | (29063.2%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$11.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Revenue: $38.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Report this figure | (4452.4%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$9.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | (4576.9%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$9.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053880.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001628280-26-053880.Report this figure | 7554.7%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $16.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figure | (2636.0%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Revenue: $222.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261. Derived: 12-month figure less the 9-month figure.Report this figure | (3904.7%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$8.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Revenue: $212.0k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | not reported (Revenue of zero not reported) | not reported (Revenue of zero not reported) | |
| Diluted EPS | $ per share | not reported (Diluted EPS not reported) | (1.69)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | (0.22)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0001739410-25-000112.Report this figure | 2.84Diluted EPS, Q3 FY2025, three months to 2025-09-30$2.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figure | not reported (Diluted EPS not reported) | (1.46)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001628280-26-034580.Report this figure | 7.53Diluted EPS, Q2 FY2026, three months to 2026-06-30$7.53 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053880.Report this figure | (0.48)Diluted EPS, Q3 FY2026, three months to 2026-09-30−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-10-27, accession 0001628280-26-067422.Report this figure | |
| Free cash flow | $k | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | 0.6Revenue, FY2024, twelve months to 2024-12-31$636.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | 0.9Revenue, FY2025, twelve months to 2025-12-31$858.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | |
| Gross margin | % | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit and Revenue not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (9511.9%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$60.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261.Revenue: $636.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | (3853.6%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$33.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261.Revenue: $858.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | |
| Net margin | % | not reported (Revenue not reported) | not reported (Revenue not reported) | not reported (Revenue not reported) | (9084.1%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$57.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261.Revenue: $636.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | (1046.4%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$9.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-16, accession 0001628280-26-018261.Revenue: $858.0k. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | |
| Diluted EPS | $ per share | (1.84)Diluted EPS, FY2021, twelve months to 2021-12-31−$1.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2023-03-06, accession 0000950170-23-006264.Report this figure | (2.09)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-12, accession 0001739410-24-000035.Report this figure | (1.84)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-13, accession 0001739410-25-000040.Report this figure | (10.61)Diluted EPS, FY2024, twelve months to 2024-12-31−$10.61 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | (1.59)Diluted EPS, FY2025, twelve months to 2025-12-31−$1.59 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-16, accession 0001628280-26-018261.Report this figure | |
| Free cash flow | $m | (45.9)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$45.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-06, accession 0000950170-23-006264.Capital expenditure: $333.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-06, accession 0000950170-23-006264.Report this figure | (57.3)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$57.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-12, accession 0001739410-24-000035.Capital expenditure: $54.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-12, accession 0001739410-24-000035.Report this figure | (60.3)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$60.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-13, accession 0001739410-25-000040.Capital expenditure: $12.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-13, accession 0001739410-25-000040.Report this figure | (49.3)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$49.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-16, accession 0001628280-26-018261.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-13, accession 0001739410-25-000040.Report this figure | not reported (Capital expenditure not reported) |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-27 | Lieber Jonathan IChief Financial Officer, Officer | Sale | 599 | $16.04 | $9.6k | Form 4 |
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 2026-06-30 | $14.8m | 926,352 | Added+905,817 | |
| CITADEL ADVISORS LLC | 2026-06-30 | $12.7m | 7,705,787 | Added+7,685,901 | |
| FMR LLC | 2026-06-30 | $12.7m | 794,720 | Added+1,269 | |
| VIKING GLOBAL INVESTORS LP | 2026-06-30 | $8.4m | 524,347 | Unchanged | |
| TPG GP A, LLC | 2026-06-30 | $6.1m | 378,551 | Unchanged | |
| Pivotal bioVenture Partners Investment Advisor LLC | 2026-06-30 | $4.8m | 300,579 | Unchanged | |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $3.2m | 199,907 | Added+43,380 | |
| Nantahala Capital Management, LLC | 2026-06-30 | $3.0m | 188,422 | Reduced−112,213 | |
| Nantahala Capital Management, LLC | 2026-06-30 | $3.0m | 188,422 | Reduced−112,213 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 2026-06-30 | $2.8m | 172,497 | Added+60,457 |
Recent filings
All 299 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2708:08 ET | 10-Q | Quarterly reportPeriod 2026-09-30 | 0001628280-26-067422 |
| 2026-10-2616:53 ET | 8-K | 8.01 Other events | 0001193125-26-432114 |
| 2026-09-0916:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-386511 |
| 2026-08-0608:03 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-053880 |
| 2026-06-0108:07 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.01 Change in control; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-249790 |
| 2026-05-1316:01 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-034580 |
| 2026-05-0616:51 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001674324-26-000004 |
| 2026-05-0407:54 ET | 8-K | 1.02 Termination of a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-202601 |
| 2026-03-3116:08 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001628280-26-022385 |
| 2026-03-1617:18 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-018261 |
Latest annual report
Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 16, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Q3 FY2026, the quarter ended 2026-09-30, has been scored from the reported figures.See the target
About the filer
- CIK
- 1739410
- Tickers
- RLYB
- Exchange
- Nasdaq
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- DE
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Former names
- Rallybio Holdings, LLC (to 2021-06-07)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:21 ET. Listed shows no prices and gives no investment advice.